RACK1 promotes the invasive activities and lymph node metastasis of cervical cancer via galectin-1

H Wu, S Song, A Yan, X Guo, L Chang, L Xu, L Hu… - Cancer letters, 2020 - Elsevier
H Wu, S Song, A Yan, X Guo, L Chang, L Xu, L Hu, M Kuang, B Liu, D He, R Zhao, L Wang…
Cancer letters, 2020Elsevier
Cervical cancer remains the first leading cause of cancer-related mortality among female
reproductive system malignancies worldwide, and invasion and lymph node metastasis of
cervical cancer represent the major reason for its poor prognosis. In this study, we found that
RACK1 facilitated tumor cell invasion and lymphatic tube formation in vitro, as well as
promoted lymphangiogenesis and lymph node metastasis in vivo in a galectin-1-dependent
manner. Mechanism studies revealed that RACK1 promoted the expression and secretion of …
Abstract
Cervical cancer remains the first leading cause of cancer-related mortality among female reproductive system malignancies worldwide, and invasion and lymph node metastasis of cervical cancer represent the major reason for its poor prognosis. In this study, we found that RACK1 facilitated tumor cell invasion and lymphatic tube formation in vitro, as well as promoted lymphangiogenesis and lymph node metastasis in vivo in a galectin-1-dependent manner. Mechanism studies revealed that RACK1 promoted the expression and secretion of galectin-1 by reducing miR-1275 levels. Additionally, RACK1 also augmented galectin-1-induced downstream MEK/ERK, FAK, and AKT signaling via integrin-β1 in cervical cancer cells. Tissue microarray confirmed that RACK1 was upregulated in squamous intraepithelial lesion and cancer, and RACK1 was positively correlated with invasion/metastasis phenotype, galectin-1 expression, and unfavorable prognosis in cervical cancer cases. Human papillomavirus E6 oncogene contributes to increased expression of RACK1 via the enhancement of its O-GlcNAcylation and protein stability. Together, our results demonstrate that RACK1 stimulates tumor invasion and lymph node metastasis of cervical cancer via galectin-1 and imply that targeting RACK1/galectin-1 axis provides promising means for cervical cancer treatment.
Elsevier